Botulinum Toxin Serotype A
Cervicobrachial Neuralgia
University of California, Los AngelesPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Cervicobrachial Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IBUPROFEN Universidad Europea de Madrid | Phase 2/3 | B |
DEXAMETHASONE Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
LIDOCAINE Centre Hospitalier Universitaire Saint Pierre | N/A | D |
Same molecule, other indications
Botulinum Toxin Serotype A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →